Meloxicam, an inhibitor of cyclooxygenase-2, increases the level of serum G-CSF and might be usable as an auxiliary means in G-CSF therapy.
Physiol Res
; 57(2): 307-310, 2008.
Article
en En
| MEDLINE
| ID: mdl-17552878
Hematopoiesis-modulating action of meloxicam, a cyclooxyge-nase-2 inhibitor, has been evaluated in mice. Increased serum level of granulocyte colony-stimulating factor (G-CSF) after meloxicam administration has been found in sublethally gamma-irradiated animals. In further experiments hematopoiesis-stimulating effects of meloxicam and G-CSF given alone or in combination have been investigated. Granulocyte/macrophage progenitor cells counts were used to monitor these effects. Meloxicam and exogenous G-CSF did not act synergistically when given in combination, but could be mutually substituted during their repeated administration. The results suggest a promising possibility of using meloxicam as an auxiliary drug reducing the high costs of G-CSF therapy of myelosuppression.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Tiazinas
/
Tiazoles
/
Médula Ósea
/
Factor Estimulante de Colonias de Granulocitos
/
Inhibidores de la Ciclooxigenasa 2
/
Hematopoyesis
Límite:
Animals
Idioma:
En
Revista:
Physiol Res
Asunto de la revista:
FISIOLOGIA
Año:
2008
Tipo del documento:
Article
País de afiliación:
República Checa
Pais de publicación:
República Checa